1-20 of 105
J. Baselga
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P2-08-19: Exploratory biomarker analyses of FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (TNBC)

MJ Wongchenko, M Oliveira, C Saura, P Nuciforo, I Calvo, J Andersen, JI Passos Coelho, M Gil Gil, B Bermejo, DA Patt, E Ciruelos, SM Singel, DJ Maslyar, N Xu, L de la Peña, J Baselga, S Gendreau, SJ Isakoff
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P2-08-19.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P2-08-19
Published: 15 February 2019
View article
Journal Articles

Abstract P4-01-03: Withdrawn

S Di Cosimo, V Appierto, S Pizzamiglio, J Baselga, M Piccart, J Huober, M Izquierdo, L de la Pena, F Hilbers, E de Azambuja, M Untch, L Pusztai, KI Pritchard, P Nuciforo, AV Salomon, FW Symmans, G Apolone, F de Braud, P Verderio, MG Daidone
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P4-01-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P4-01-03
Published: 15 February 2019
View article
Journal Articles

Abstract P5-04-11: Non-canonical, clinical ESR1 mutations promote resistance to antiestrogen therapies

W Toy, KE Carlson, TA Martin, P Razavi, M Berger, J Baselga, G Greene, J Katzenellenbogen, S Chandarlapaty
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P5-04-11.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P5-04-11
Published: 15 February 2019
View article
Journal Articles

Abstract P6-18-30: Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC)

R Wang, J Singh, V Sterlin, M Goldstein, D Lake, S Wong, J Baselga, L Norton, C Dang
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P6-18-30.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P6-18-30
Published: 15 February 2019
View article
Journal Articles

Abstract P6-17-10: Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analyses

K Tamura, S Modi, J Tsurutani, S Takahashi, IE Krop, H Iwata, R Wada, O Yin, T Garimella, M Sugihara, L Zhang, C Lee, A Yver, J Baselga
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P6-17-10.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P6-17-10
Published: 15 February 2019
View article
Journal Articles

Abstract PD3-06: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT trial

LM Smyth, SA Piha-Paul, C Saura, S Loi, J Lu, GI Shapiro, D Juric, IA Mayer, C Arteaga, M de la Fuente, AM Brufksy, M Mau-Sørensen, M Arnedos, V Moreno, J-H Sohn, L Schwartzberg, X Gonzàlez-Farré, A Cervantes, G Mann, S Shahin, RE Cutler, Jr., LD Eli, F Xu, T Bagulho, AS Lalani, R Bryce, DB Solit, DM Hyman, F Meric-Bernstam, J Baselga
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): PD3-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-PD3-06
Published: 15 February 2019
View article
Journal Articles

Abstract PD3-03: Circulating tumor DNA in HER2 amplified breast cancer: A translational research substudy of the NeoALTTO phase 3 trial

M Ignatiadis, MJ Silva, C Campbell, I Bradbury, E de Azambuja, M Maetens, D Fumagalli, V Rodrik-Outmezguine, S Di Cosimo, D Rosa, S Chia, A Wardley, T Ueno, W Janni, J Huober, J Baselga, M Piccart, C Sotiriou, S Loi, F Rothé, S Dawson
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): PD3-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-PD3-03
Published: 15 February 2018
View article
Journal Articles

Abstract PD5-12: Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Overall survival (OS) results from BELLE-2, a randomized, phase III study

M Campone, S-A Im, H Iwata, M Clemons, Y Ito, A Awada, S Chia, A Jagiełło-Gruszfeld, B Pistilli, L-M Tseng, S Hurvitz, N Masuda, J Cortés, M De Laurentiis, CL Arteaga, Z Jiang, W Jonat, D Sellami, M El-Hashimy, S Le Mouhaër, B Sankaran, L Bourdeau, J Baselga
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): PD5-12.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-PD5-12
Published: 15 February 2018
View article
Journal Articles

Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer

E de Azambuja, C Saura, P Nuciforo, S Frantal, M Oliveira, D Zardavas, A Jallitsch-Halper, L de la Pena, P Dubsky, JM Lombard, P Vuylsteke, C Castaneda Altamirano, C Sanchez, A Ballestrero, M Colleoni, G Santos Borges, E Ciruelos, A Bardia, M Fornier, K Boer, TR Wilson, TJ Stout, JY Hsu, Y Shi, M Piccart, J Baselga, M Gnant
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): PD5-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-PD5-04
Published: 15 February 2018
View article
Journal Articles

Abstract P1-13-07: Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-Positive breast cancer

J Bines, E de Azambuja, D Zardavas, M Procter, E Restuccia, G Viale, T Suter, A Arahmani, V van Dooren, E Clark, J Eng-Wong, R Gelber, M Piccart, G von Minckwitz, J Baselga
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P1-13-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P1-13-07
Published: 15 February 2018
View article
Journal Articles

Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial

D Venet, F Rothé, F Dupont, M Maetens, D Fumagalli, R Salgado, I Bradbury, L Pusztai, N Harbeck, M Izquierdo, L de la Pena, M Ignatiadis, E de Azambuja, J Huober, P Nuciforo, J Baselga, M Piccart, S Loi, C Sotiriou
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P2-05-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P2-05-04
Published: 15 February 2018
View article
Journal Articles

Abstract P2-09-07: Low levels of HER2 extracellular domain (ECD) compared to intracelluar domain (ICD) in NeoALTTO may segregate benefit from lapatinib and trastuzumab in breast cancer

DL Rimm, D Carvajal-Hausdorf, N Harbeck, D Fumagalli, V Rodrik-Outmezguine, L delaPena, E deAzambuja, J Huober, J Baselga, M Piccart, E Holmes, L Pusztai
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P2-09-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P2-09-07
Published: 15 February 2018
View article
Journal Articles

Abstract P2-09-01: T-cell receptor beta chain variable region (TRBV) expression patterns predict response to combined trastuzumab/lapatinib treatment in the NeoALTTO/BIG-1-06 trial

R Powles, D Redmond, C Sotiriou, S Loi, D Fumagalli, P Nuciforo, N Harbeck, E de Azambuja, S Sarp, S Di Cosimo, J Huober, J Baselga, M Piccart-Gebhart, O Elemento, C Hatzis, L Pusztai
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P2-09-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P2-09-01
Published: 15 February 2018
View article
Journal Articles

Abstract P2-09-20: Biomarker analysis of the LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) in metastatic triple-negative breast cancer (TNBC)

MJ Wongchenko, R Dent, S-B Kim, C Saura, M Oliveira, J Baselga, AV Kapp, WY Chan, SM Singel, DJ Maslyar, S Gendreau
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P2-09-20.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P2-09-20
Published: 15 February 2018
View article
Journal Articles

Abstract P2-09-03: Identifying clinically relevant subgroups of women with HER2-positive breast cancer: An analysis of Neo-ALTTO using the 41-gene TRAR score

S Di Cosimo, T Triulzi, L De Cecco, S Pizzamiglio, E de Azambuja, D Fumagalli, L Pusztai, N Harbeck, M Izquierdo, L de la Pena, J Huober, J Baselga, M Piccart, P Verderio, E Tagliabue
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P2-09-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P2-09-03
Published: 15 February 2018
View article
Journal Articles

Abstract P1-07-09: Serum activin A and outcomes in HR+ /HER2- metastatic breast cancer patients treated with everolimus: Results from BOLERO-2

SM Ali, D Chen, A Ali, L Krecko, K Leitzel, M Vasekar, V Nagabhairu, E Marks, H Polimera, A Richardson, M May, W He, P Patel, M Lavin, S Hofsess, R Sweetman, G Hortobagyi, J Baselga, A Lipton
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P1-07-09.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P1-07-09
Published: 15 February 2018
View article
Journal Articles

Abstract P5-21-05: Withdrawn

LM Smyth, M Oliveira, E Ciruelos, K Tamura, A El-Khoueiry, A Mita, B You, DJ Renouf, M-P Sablin, A Lluch, IA Mayer, H Bando, H Yamashita, H Ambrose, E de Bruin, TH Carr, C Corcoran, A Foxley, JPO Lindemann, R Maudsley, M Pass, A Rutkowski, G Schiavon, U Banerji, M Scaltriti, BS Taylor, S Chandarlapaty, J Baselga, DM Hyman
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P5-21-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P5-21-05
Published: 15 February 2018
View article
Journal Articles

Abstract P5-21-32: AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer

LM Smyth, M Oliveira, E Ciruelos, K Tamura, A El-Khoueiry, A Mita, B You, DJ Renouf, M-P Sablin, A Lluch, IA Mayer, H Bando, H Yamashita, H Ambrose, E de Bruin, TH Carr, C Corcoran, A Foxley, JPO Lindemann, R Maudsley, M Pass, A Rutkowski, G Schiavon, U Banerji, M Scaltriti, BS Taylor, S Chandarlapaty, J Baselga, DM Hyman
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P5-21-32.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P5-21-32
Published: 15 February 2018
View article
Journal Articles

Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial

C Sotiriou, F Rothé, M Maetens, D Fumagalli, DN Brown, R Salgado, I Bradbury, L Pusztai, N Harbeck, M Ignatiadis, S Sarp, L de la Pena, E de Azambuja, J Huober, P Nuciforo, J Baselga, M Piccart, S Loi, D Venet
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): GS1-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-GS1-04
Published: 15 February 2018
View article
Journal Articles

Abstract S3-02: Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO

S Di Cosimo, V Appierto, P Tiberio, P Verderio, S Pizzamiglio, S Bottelli, M Iorio, J Baselga, M Piccart, J Huober, J Brase, L de la Pena, D Fumagalli, E de Azambuja, F de Braud, MG Daidone
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): S3-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-S3-02
Published: 15 February 2017
View article